BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X, Chen Y, Wu JJ. First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients. Medicine (Baltimore) 2020;99:e23357. [PMID: 33235105 DOI: 10.1097/MD.0000000000023357] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Derruau S, Bouchet J, Nassif A, Baudet A, Yasukawa K, Lorimier S, Prêcheur I, Bloch-Zupan A, Pellat B, Chardin H, Jung S, On Behalf Of Task Force Covid-Collège National des EnseignantS En Biologie Orale Cnesbo-France. COVID-19 and Dentistry in 72 Questions: An Overview of the Literature. J Clin Med 2021;10:779. [PMID: 33669185 DOI: 10.3390/jcm10040779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, Tanzifi A, Faramarzi F, Negarandeh R, Safdari M, Khataminia M, Rezai Ghaleno H, Habtemariam S, Khoshi A. Pharmacological treatments of COVID-19. Pharmacol Rep 2020;72:1446-78. [PMID: 32816200 DOI: 10.1007/s43440-020-00152-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
3 Wang WJ, Chen Y, Su WC, Liu YY, Shen WJ, Chang WC, Huang ST, Lin CW, Wang YC, Yang CS, Hou MH, Chou YC, Wu YC, Wang SC, Hung MC. Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2. J Food Biochem 2022;:e14354. [PMID: 35894128 DOI: 10.1111/jfbc.14354] [Reference Citation Analysis]
4 Ahmed FF, Reza MS, Sarker MS, Islam MS, Mosharaf MP, Hasan S, Mollah MNH. Identification of host transcriptome-guided repurposable drugs for SARS-CoV-1 infections and their validation with SARS-CoV-2 infections by using the integrated bioinformatics approaches. PLoS One 2022;17:e0266124. [PMID: 35390032 DOI: 10.1371/journal.pone.0266124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Fouka E, Kalomenidis I, Gianniou N, Gida S, Steiropoulos P. COVID-19 Advanced Care. J Pers Med 2021;11:1082. [PMID: 34834434 DOI: 10.3390/jpm11111082] [Reference Citation Analysis]
6 Farhat A, Ben Hlima H, Khemakhem B, Ben Halima Y, Michaud P, Abdelkafi S, Fendri I. Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach. Bioengineered 2022;13:3350-61. [PMID: 35048792 DOI: 10.1080/21655979.2022.2027181] [Reference Citation Analysis]
7 Afshar-Oromieh A, Prosch H, Schaefer-Prokop C, Bohn KP, Alberts I, Mingels C, Thurnher M, Cumming P, Shi K, Peters A, Geleff S, Lan X, Wang F, Huber A, Gräni C, Heverhagen JT, Rominger A, Fontanellaz M, Schöder H, Christe A, Mougiakakou S, Ebner L. A comprehensive review of imaging findings in COVID-19 - status in early 2021. Eur J Nucl Med Mol Imaging 2021;48:2500-24. [PMID: 33932183 DOI: 10.1007/s00259-021-05375-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
8 Ghanbari R, Teimoori A, Sadeghi A, Mohamadkhani A, Rezasoltani S, Asadi E, Jouyban A, Sumner SC. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients. Future Microbiol 2020;15:1747-58. [PMID: 33404263 DOI: 10.2217/fmb-2020-0120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Li CX, Noreen S, Zhang LX, Saeed M, Wu PF, Ijaz M, Dai DF, Maqbool I, Madni A, Akram F, Naveed M, Li JH. A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies. Biomed Pharmacother 2021;146:112550. [PMID: 34959116 DOI: 10.1016/j.biopha.2021.112550] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
10 Jonny, Violetta L, Kartasasmita AS, Amirullah Roesli RM, Rita C. Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. Int J Nephrol 2021;2021:4078713. [PMID: 34858665 DOI: 10.1155/2021/4078713] [Reference Citation Analysis]
11 Antonopoulou I, Sapountzaki E, Rova U, Christakopoulos P. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
12 Singh Y, Raza H, Sharma SK, Bhat VK. Computing Basis and Dimension of Chloroquine and Hydroxychloroquine by Using Chemical Graph Theory. Polycyclic Aromatic Compounds. [DOI: 10.1080/10406638.2022.2086269] [Reference Citation Analysis]
13 Adibzadeh S, Amiri S, Nia GE, Taleghani MR, Bijarpas ZK, Maserat N, Maali A, Azad M, Behzad-Behbahani A. Therapeutic approaches and vaccination in fighting COVID-19 infections: A review. Gene Rep 2022;:101619. [PMID: 35530725 DOI: 10.1016/j.genrep.2022.101619] [Reference Citation Analysis]
14 Amini Pouya M, Afshani SM, Maghsoudi AS, Hassani S, Mirnia K. Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. Daru 2020;28:745-64. [PMID: 32734518 DOI: 10.1007/s40199-020-00359-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wang D, Li Z, Liu Y. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. J Infect Public Health 2020;13:1405-14. [PMID: 32684351 DOI: 10.1016/j.jiph.2020.07.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
16 Citarella A, Scala A, Piperno A, Micale N. SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules 2021;11:607. [PMID: 33921886 DOI: 10.3390/biom11040607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Gupta A, Pradhan A, Maurya VK, Kumar S, Theengh A, Puri B, Saxena SK. Therapeutic approaches for SARS-CoV-2 infection. Methods 2021:S1046-2023(21)00126-2. [PMID: 33962011 DOI: 10.1016/j.ymeth.2021.04.026] [Reference Citation Analysis]
18 Miroshnychenko KV, Shestopalova AV. Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study. J Biomol Struct Dyn 2021;:1-15. [PMID: 33896392 DOI: 10.1080/07391102.2021.1914168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]